Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Pipeline Review, H2 2016’, provides in depth analysis on Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted pipeline therapeutics.

The report provides comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)

The report reviews Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics and enlists all their major and minor projects

The report assesses Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Agilvax Inc

Bavarian Nordic A/S

Emergent BioSolutions Inc

F. Hoffmann-La Roche Ltd

Trellis Bioscience Inc

Visterra Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) Overview 6

Therapeutics Development 7

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Products under Development by Stage of Development 7

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Products under Development by Therapy Area 8

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Products under Development by Indication 9

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Products under Development by Companies 12

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Products under Development by Universities/Institutes 14

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Companies Involved in Therapeutics Development 22

Agilvax Inc 22

Bavarian Nordic A/S 23

Emergent BioSolutions Inc 24

F. Hoffmann-La Roche Ltd 25

Trellis Bioscience Inc 26

Visterra Inc 27

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Drug Profiles 28

AX-14 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

MVA-RSV - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

respiratory syncytial virus vaccine - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

respiratory syncytial virus vaccine - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

TRL-3D3 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

VIS-RSV - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Dormant Projects 37

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Featured News & Press Releases 38

Dec 14, 2016: Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine 38

Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine 38

Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At International RSV Symposium 39

Jul 06, 2016: Agilvax Receives SBIR Grant To Advance Development Of A VLP Based RSV Vaccine 39

May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations 39

Aug 18, 2015: Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN in Respiratory Syncitial Virus 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Agilvax Inc, H2 2016 22

Pipeline by Bavarian Nordic A/S, H2 2016 23

Pipeline by Emergent BioSolutions Inc, H2 2016 24

Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 25

Pipeline by Trellis Bioscience Inc, H2 2016 26

Pipeline by Visterra Inc, H2 2016 27

Dormant Projects, H2 2016 37

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports